4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Autoimmune Hepatitis by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 69 ongoing clinical trials involving Autoimmune Hepatitis
Of the 69 trials,29 trials are in Phase II/III
Furthermore, 21 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Autoimmune Hepatitis by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Autoimmune Hepatitis, a Gastrointestinal indication. Asia-Pacificand Europe are among some of the prominent regions involved in Autoimmune Hepatitis-related drug trials.

West China Hospital: The leading ongoing Autoimmune Hepatitis related clinical trial sponsor

West China Hospital is the top sponsor for Autoimmune Hepatitis-related ongoing clinical trials.

West China Hospital of Sichuan University, University of Birmingham, Tel Aviv Sourasky Medical Center, and Catholic University of Louvainare a few other notable clinical trial sponsors involved in Autoimmune Hepatitis. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Autoimmune Hepatitis

Azathioprine (Thioprine, Azapressin), Azathrioprine (Imuran, Imurel, Imurek, Azran, Imuran Mitis), Cyclosporine (PanimunBioral), and Betamethasone (Betamethasone)are among the key marketed drugs involving Autoimmune Hepatitis.

Azathrioprine (Imuran, Imurel, Imurek, Azran, Imuran Mitis) is an immunosuppressive agent. It functions via Hypoxanthine Guanine Phosphoribosyltransferase (HPRT1 or EC 2.4.2.8) Inhibitor mechanism of action. It is formulated as film coated tablets, tablets for oral route and powder for solution for intravenous route of administration. Imuran is marketed for the treatment of Autoimmune Hepatitis and several other indications including Arthritis, Inflammatory Bowel Disease, Liver Transplant Rejection, Heart Transplant Rejection, Vasculitis, Lung Transplant Rejection, Polymyositis, Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), and Lupus Erythematosus, Dermatomyositis. Azathrioprine was first approved in 1965 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by Aspen Pharmacare Holdings Ltd and several other companies including Sebela Pharmaceuticals Inc, H.A.C. Pharma, and GlaxoSmithKline plc.

Betamethasone is a corticosteroid, anti-inflammatory drug and an immunosuppressive agent. It functions via Glucocorticoid Receptor (GR or Nuclear Receptor Subfamily 3 Group C Member 1 or NR3C1) Agonist mechanism of action. It is formulated as drops for oral route of administration. Betamethasone is marketed for the treatment of Autoimmune Hepatitis and several other indications includingNeuropathic Pain (Neuralgia), Arthritis, Asthma, Lupus Nephritis, Dermatosis, Glomerulonephritis, Myasthenia Gravis, Sarcoidosis, Vasculitis, Chronic Obstructive Pulmonary Disease (COPD), Polymyositis, and Cirrhosis. Betamethasonewas first approved in 2008 and is marketed in France by Arrow Generiques SAS